Document Detail


Dynamic contrast-enhanced MRI in ovarian cancer: Initial experience at 3 tesla in primary and metastatic disease.
MedLine Citation:
PMID:  20373405     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The aim of this study was to develop and demonstrate a methodology for dynamic contrast-enhanced MRI at 3 T in patients with advanced ovarian cancer and to report the results from pharmacokinetic modeling of the data. Nineteen patients with suspected advanced ovarian carcinoma (FIGO stage 3 or higher) were enrolled in this prospective study. Up to three marker lesions were identified: primary ovarian mass, omental ''cake'', and peritoneal deposits. Dynamic contrast-enhanced MRI was performed using a three-dimensional T(1)-weighted gradient-echo acquisition with a temporal resolution of 1.6 sec, following intravenous administration of 0.1 mmol/kg gadobutrol. Precontrast T(1) mapping, using an inversion-recovery fast gradient-echo sequence, was also performed. Imaging was completed in 18/19 patients, although two were subsequently excluded based on pathology results. Pharmacokinetic modeling of the data was performed according to the extended Kety model, using an arterial input function formed by concatenation of the Fritz-Hansen and Weinmann curves. No statistically significant differences were found between the results for the three marker lesions. In the future, this work will allow kinetic modeling results from ovarian dynamic contrast-enhanced MRI to be correlated with response to treatment. The high temporal resolution allows good characterization of the rapid contrast agent uptake in these vascular tumors.
Authors:
Andrew N Priest; Andrew B Gill; Masako Kataoka; Mary A McLean; Ilse Joubert; Martin J Graves; John R Griffiths; Robin A F Crawford; Helena Earl; James D Brenton; David J Lomas; Evis Sala
Related Documents :
18349315 - Gliomas: predicting time to progression or survival with cerebral blood volume measurem...
7422835 - A strategy for the contrast enhancement of malignant tumors using dynamic computed tomo...
16398415 - Cluster analysis of dynamic cerebral contrast-enhanced perfusion mri time-series.
21739095 - Semicircular canal dehiscence in hr multislice computed tomography: distribution, frequ...
9601965 - The pelvis after surgery and radio-chemotherapy for rectal cancer studied with gd-dtpa-...
1749845 - Value of mr imaging in evaluating focal fatty infiltration of the liver: preliminary st...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Magnetic resonance in medicine : official journal of the Society of Magnetic Resonance in Medicine / Society of Magnetic Resonance in Medicine     Volume:  63     ISSN:  1522-2594     ISO Abbreviation:  Magn Reson Med     Publication Date:  2010 Apr 
Date Detail:
Created Date:  2010-04-07     Completed Date:  2010-07-15     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8505245     Medline TA:  Magn Reson Med     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1044-9     Citation Subset:  IM    
Affiliation:
Department of Radiology, Addenbrooke's Hospital, Cambridge, UK. andrew.priest@addenbrookes.nhs.uk
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adenocarcinoma / drug therapy,  pathology*
Aged
Contrast Media / pharmacokinetics
Female
Humans
Magnetic Resonance Imaging / methods*
Middle Aged
Neoplasm Staging
Organometallic Compounds / pharmacokinetics
Ovarian Neoplasms / drug therapy,  pathology*
Prospective Studies
Statistics, Nonparametric
Grant Support
ID/Acronym/Agency:
//Cancer Research UK
Chemical
Reg. No./Substance:
0/Contrast Media; 0/Organometallic Compounds; 138071-82-6/gadobutrol

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Gene expression profiling reveals early cellular responses to intracellular magnetic labeling with s...
Next Document:  Optimization of encoding gradients for MR-ARFI.